BCB Bancorp has had a remarkable ten days — a Q1 earnings beat sent the stock surging, shorts retreated sharply, and options positioning flipped from heavily defensive to the most bullish it has been in months.
The Q1 print on April 21 was the catalyst. BCBP delivered EPS of $0.26, beating the $0.20 consensus by five cents, though revenue of $24.9M came in just below the $25.8M estimate. The market focused on the bottom line. The stock rose 5.5% on the day and is up 11.6% over the five days that followed. From the April low near $8.20, the stock has now climbed to $10.43 — a gain of more than 20% in a single month.
Options positioning captures the shift in sentiment most vividly. For most of the prior six weeks, the put/call ratio ran well above 1.0 — hitting as high as 2.04 in early April — reflecting deep hedging and outright bearish bets ahead of the earnings release. After the print, that positioning unwound almost completely. The PCR has collapsed to 0.43, now 1.34 standard deviations below its 20-day mean of 1.31. Investors who were paying for protection have either closed those positions or rolled into calls. The contrast with where options sentiment stood just two weeks ago is striking.
Short sellers have drawn the same conclusion. Short interest fell roughly 11% over the week to around 2.8% of the free float — not a crowded position by any measure, but the direction of travel matters. The sharpest drop came on April 23-24, when estimated shares short fell from ~550,000 to ~479,000 in a single session. Borrowing costs reflect the absence of conviction on the short side too: cost to borrow has eased to just 0.51% — down 28% on the week and near the lowest level of the past six weeks. Availability in the lending market remains loose, consistent with a stock where short sellers are not competing hard for the remaining borrow.
Piper Sandler moved quickly after the Q1 release, raising its price target from $9.00 to $11.00 on April 22 while keeping its Neutral rating intact. The current stock price at $10.43 is already nudging up against that revised target, which puts the Street in an awkward spot. The analyst bull case centres on NIM expansion potential in the second half of 2026 and the bank's ongoing efforts to stabilise credit quality after a difficult 2025 — when a large OREO writedown drove a net loss. The bear case holds that nonaccruals and classified loans remain elevated, and any further deterioration in asset quality could reverse recent progress. EPS momentum factor scores rank in the 93rd and 92nd percentile on both 30- and 90-day windows, and the 12-month forward EPS growth estimate ranks in the 94th percentile — consistent with a market reassessing how far earnings recovery has already run. The price-to-book multiple has expanded around 10 points over the past month to 0.61x, still well below tangible book, which remains either an attraction or a caution flag depending on which credit scenario you assign.
Insider buying adds a layer of context to the recovery story. Chairman Mark Hogan bought 5,000 shares at $7.97 in late February, adding to a pattern of purchases — including a 10,000-share buy in June 2025 at $7.74. Director Michael Widmer also bought 2,000 shares in February. Net insider purchases over the 90 days to late February totalled approximately $56,650. Those buys were made near multi-year lows; the stock has since risen more than 30% from those levels. Importantly, no insider sales have been filed in the period since then. The shareholder vote filing on April 28 — an 8-K disclosing matters submitted to a vote of security holders — is the most recent regulatory submission, though no material detail was disclosed publicly.
Among correlated regional bank peers, CATY rose 4.1% on the week and EFSC added 3.2%, but both lag BCBP's 6.4% weekly gain by a meaningful margin. EFSI was the one outlier, falling 1.2% on the week. The regional bank group broadly reflected post-earnings optimism, but BCBP's move stands out relative to the cohort. What to watch from here is whether credit quality data at the next quarterly update corroborates the recovery narrative — particularly on nonaccruals and classified loan trends — or whether the stock's rapid re-rating outruns the pace of balance sheet improvement.
See the live data behind this article on ORTEX.
Open BCBP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
